The code-named 'RCI002' that this company has récemment been researching and developing is a project to create a protein thérapeutique with pain-relieving effects. This treatment is produced by synthesizing a protein gene in E. coli, expressing it, and then extracting the thérapeutique substance. The approach involves optimizing a protein found in vivo and recombining it into a thérapeutique capable of suppressing pain in the body over a prolonged period.
L'entreprise explained that this substance demonstrated a pain-free duration nearly 20 times longer than gabapentin — a pain reliever commonly administered in general hospitals for douleur chronique management. When 65 mg/kg of gabapentin (sur la base de body weight) was administered to mice, soulagement de la douleur lasted about 4 hours, but when only 0.1 mg/kg of the RCI002 substance was administered, soulagement de la douleur lasted approximately 3 days.
RudaCure is developing a gene therapy approach that relieves and treats douleur chronique using a protein gene that regulates douleur chronique in vivo. This is because a single injection can be expected to provide effets thérapeutiques for 2–3 years. le PDG Kim a déclaré : "Pain relievers, local anesthetics, and analgésiques narcotiques used in general hospitals are not fundamental treatments," adding, "Narcotic analgésiques lose their effectiveness as tolerance develops or cause addiction."